BioSpace News Archive

Solid tumor-specific scaffold protein ligands from Navigo combined with MDimune’s BioDrone® technology to create novel targeted extracellular vesicle-based therapeutics

Prometheus Laboratories, Inc. (“Prometheus”), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21st Annual Pain Therapeutics Conference.

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced record results for the first quarter ended March 31, 2021.

Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months ended March 31, 2021, and provided a corporate update.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that it will report financial results for the fiscal quarter ended March 31, 2021 after the market closes on Monday, May 17, 2021.

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share.

Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the first quarter ended March 31, 2021.